- How is Hodgkin disease treated?
- Chemotherapy for Hodgkin disease
- Radiation therapy for Hodgkin disease
- Monoclonal antibodies for Hodgkin disease
- High-dose chemotherapy and stem cell transplant for Hodgkin disease
- Clinical trials for Hodgkin disease
- Complementary and alternative therapies for Hodgkin disease
- Treating classic Hodgkin disease, by stage
- Treating nodular lymphocyte predominant Hodgkin disease (NLPHD)
- Treating Hodgkin disease in children
- Hodgkin disease in pregnancy
- More treatment information
Monoclonal antibodies for Hodgkin disease
Antibodies are proteins made by your immune system to help fight infections. Man-made versions, called monoclonal antibodies (mAbs), can be designed to attack a specific target, such as a substance on the surface of lymphocytes (the cells in which Hodgkin disease starts).
Some mAbs are now being used to treat Hodgkin disease.
Brentuximab vedotin (Adcetris®): This drug is an anti-CD30 antibody attached to a chemotherapy drug. Hodgkin disease cells usually have the CD30 molecule on their surface. The antibody acts like a homing signal, bringing the chemo drug to the lymphoma cells, where it enters the cells and makes them die when they try to divide into new cells.
This drug has been shown to help many people whose Hodgkin disease has come back after other treatments, including a stem cell transplant, as well as people who can’t have a stem cell transplant. It is also being studied to see if it can be given with chemotherapy and if can be helpful earlier in the course of the disease.
Brentuximab is infused into a vein (IV) every 3 weeks. Common side effects include nerve damage (neuropathy), low blood cell counts, fatigue, fever, nausea and vomiting, infections, diarrhea, and cough. Rarely, serious side effects occur during infusions, such as trouble breathing and low blood pressure.
Rituximab (Rituxan®): This antibody attaches to a substance called CD20 found on some types of lymphoma cells, which seems to kill the lymphoma cell. Rituximab may be used to treat nodular lymphocyte predominant Hodgkin disease (NLPHD), often with chemotherapy and/or radiation therapy.
Rituximab is given as an IV infusion in the doctor’s office or clinic. When it is used by itself, it is usually given once a week for 4 weeks, which may then be repeated several months later. When it is combined with chemotherapy, it is most often given on the first day of each chemo cycle.
Common side effects are usually mild but can include chills, fever, nausea, rashes, fatigue, and headaches. Rarely, more severe side effects occur during infusions, such as trouble breathing and low blood pressure. Even if these symptoms occur during the first infusion, it is very unusual for them to recur with later doses. Rituximab can cause prior hepatitis B infections to become active again, sometimes leading to severe liver problems or even death. Your doctor will probably check your blood for signs of hepatitis before starting this drug. This drug can also increase the risk of certain infections for several months after the drug is stopped.
Last Medical Review: 07/10/2014
Last Revised: 01/13/2015